8 results
Primary objective(s)Phase Ib:-Define the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD) of AUY922 in combination with Trastuzumab in patients with advanced or metastatic HER2-positive breast cancers.Phase II:-Evaluate…
Primary objectives Phase Ib: To estimate the MTD and/or RP2D of LGX818 in combination with cetuximab ± BYL719. Incidence of dose-limiting toxicities (DLTs). Phase II: To compare the efficacy of the dual (LGX818, cetuximab) and triple (LGX818, BYL719…
Primary objective: To determine the MTD/highest studied dose determined to be safe, the safety and tolerability of INC280 as a single agent when administered orally to adult patients with c-MET dependent advanced solid malignancies.Secondary…
Primary Objective: Major amputation rate after 12-months of follow-upSecondary Objectives: - Amputation-free survival- Health-related quality of life- Complete wound healing- Pain scores- Need for additional (vascular) interventions- Cost-…
The primary objective of the trial is to assess a non-flat dose-response curve and to evaluate the dose-response relationship for 3 oral dose regimens of BI 1291583 versus placebo, on the primary endpoint, time to first pulmonary exacerbation up to…
The aim of this phase 2 study is to investigate the safety and efficacy of dazucorilant in the target ALS patient population.
To investigate the therapeutic efficacy and feasibility of hyperbaric oxygen (HBO) in addition to standard wound care in patients with pyoderma gangrenosum wounds.
Part 1 of the trial (already completed):The primary objective of the research concerned the determination of the Maximum Tolerated Dose (MTD) and/or Maximum Recommended Dose (MRD) of MCLA-128. Which was set to 750mg.The secundary objective of the…